ARG-007 Efficacious Dose Validated in New Preclinical Study

• Argenica engaged clinical research organisation MD Biosciences to independently validate the efficacy of ARG-007 in a rat model of ischemic stroke that mimics human large vessel occlusion strokes to provide further conviction on the efficacy and dosing of ARG-007. • Consistent with previous studies conducted by Argenica’s Chief Scientific Officer at the Perron Institute, a dose of 325 nmol/kg AR